extract: 2026-03-30-jacc-cvd-mortality-trends-1999-2023

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -72,6 +72,12 @@ Amodei's complementary factors framework explicitly identifies 'human constraint
 
 PNAS 2026 attributes US life expectancy stagnation to 'a complex convergence of rising chronic disease, shifting behavioral risks, and increases in certain cancers among younger adults' — explicitly identifying behavioral and social factors as the drivers of cohort-level mortality deterioration, not medical care quality.
 
+### Additional Evidence (confirm)
+*Source: [[2026-03-30-jacc-cvd-mortality-trends-1999-2023]] | Added: 2026-03-30*
+
+Hypertension-related CVD mortality doubled 2000-2023 (23→43 per 100,000) despite widespread availability of effective, cheap generic antihypertensives. This is the strongest single empirical case for the 80-90% non-clinical determinants thesis because the failure occurs despite pharmacological solutions being universally accessible, proving the constraint is behavioral/SDOH not medical.
+
+
 
 Relevant Notes:
 - [[social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem]] -- loneliness is one of the most actionable SDOH factors with clear cost signature and robust evidence

domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md

@@ -19,6 +19,12 @@ The JACC study tracking 1999-2023 NHANES data reveals a striking failure mode in
 
 ---
 
+### Additional Evidence (extend)
+*Source: [[2026-03-30-jacc-cvd-mortality-trends-1999-2023]] | Added: 2026-03-30*
+
+The population-level outcome of poor blood pressure control manifests as doubled hypertensive disease mortality 2000-2023, with 664,000 deaths in 2023 where hypertension was primary or contributing cause. Middle-aged adults (35-64) showed the most pronounced increases, indicating the treatment failure compounds over working-age years.
+
+
 Relevant Notes:
 - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 - [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]

domains/health/pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling.md

@@ -30,6 +30,12 @@ This is direct quantitative evidence that the 'pharmacological ceiling' in US ca
 
 Large US claims database (2015-2021) shows PCSK9 penetration rose from 0.05% in Q3 2015 to only 2.5% by Q2 2019 — four years post-FDA approval. Overall penetration: 0.9% of ASCVD patients on statin therapy filled a PCSK9 prescription (126,419 patients). Only 49.93% of written PCSK9 prescriptions were successfully filled (vs 68-84% for comparable branded cardiometabolic therapies). Hospitalized ASCVD patients (2020-2022) received PCSK9 inhibitors at only 1.3% rate despite hospitalization providing ideal prescribing opportunity. Commercial insurance rejection: 69.5%; Medicare: 42.3%. The 2018 price reduction (from ~$14,000/year to ~$5,800/year) improved adherence in commercially insured patients but did NOT produce population-level penetration increase.
 
+### Additional Evidence (extend)
+*Source: [[2026-03-30-jacc-cvd-mortality-trends-1999-2023]] | Added: 2026-03-30*
+
+The CVD stagnation mechanism has three distinct layers: (1) pharmacological saturation where statins succeeded in reducing ischemic disease, (2) access-mediated ceilings where PCSK9 inhibitors cannot reach patients despite efficacy, and (3) behavioral/SDOH treatment failure where hypertensive disease mortality doubled despite cheap, accessible medications. This third layer was previously missing from the CVD stagnation hypothesis.
+
+
 
 Relevant Notes:
 - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]

inbox/queue/2026-03-30-jacc-cvd-mortality-trends-1999-2023.md

@@ -7,9 +7,13 @@ date: 2025-06-01
 domain: health
 secondary_domains: []
 format: journal-article
-status: unprocessed
+status: enrichment
 priority: high
 tags: [CVD-mortality, hypertension, ischemic-heart-disease, trends, United-States, JACC, 2023, age-standardized, midlife]
+processed_by: vida
+processed_date: 2026-03-30
+enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -62,3 +66,14 @@ These two trajectories coexisting reveals that the pharmacological ceiling story
 PRIMARY CONNECTION: [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]] — parallel structural failure
 WHY ARCHIVED: The hypertension mortality doubling is the third layer of the CVD stagnation argument that was previously missing from the KB. It also directly evidences Belief 2 (80-90% non-clinical) because the failure occurs despite widely available, cheap, effective drugs.
 EXTRACTION HINT: Extract as a claim about hypertension-specific mortality trends, distinct from the general "US CVD stagnation" claim. The key argumentative move is: ischemic disease improved (medicine worked) + hypertensive disease doubled (medicine failed despite availability) = the failure is behavioral/SDOH, not pharmacological. This is the strongest direct evidence for Belief 2 in the health domain.
+
+
+## Key Facts
+- Ischemic heart disease age-standardized mortality rate declined 1999-2023 in the United States
+- Hypertensive disease contributed to approximately 664,000 deaths in 2023 as primary or contributing cause
+- Cardiomyopathy mortality declined 1999-2023
+- Arrhythmia mortality increased 1999-2023
+- Pulmonary heart disease mortality increased 1999-2023
+- CVD accounted for 915,973 deaths in 2023 with US age-adjusted mortality rate of 218.3 per 100,000
+- 2022 CVD AAMR (434.6) remains higher than pre-pandemic 2019 levels
+- 190,661 excess CVD deaths occurred 2020-2022